Intilin-P Syrup is a combination pharmaceutical formulation containing Citicoline 500mg and Piracetam 400mg per 5ml, designed to support cognitive function and neuroprotection. Citicoline, a neuroprotective agent, enhances brain metabolism by increasing phosphatidylcholine synthesis, thereby promoting neuronal membrane repair and improving neurotransmitter synthesis, particularly acetylcholine. Piracetam, a nootropic agent, modulates neuronal excitability and enhances neuroplasticity by influencing membrane fluidity and ion channels, leading to improved cognitive processes such as memory, attention, and learning. Intilin-P Syrup is indicated for the management of cognitive impairments associated with cerebrovascular diseases, dementia, traumatic brain injury, and other neurodegenerative conditions. It may also be utilized as an adjunct therapy in patients with stroke or age-related cognitive decline. The syrup formulation ensures ease of administration, especially in pediatric and geriatric populations. Dosage and duration of treatment should be individualized based on clinical response and physician assessment. Common adverse effects are generally mild and may include gastrointestinal disturbances or headache. Intilin-P Syrup should be used under medical supervision, with caution in patients with hypersensitivity to its components or underlying medical conditions. Regular monitoring is advised to evaluate therapeutic efficacy and tolerability.